Most Recent Stories
More News
In today’s highly volatile market, this simple 3-ETF portfolio combines both steady income and long-term upside.
Global data from over 12,000 consumers signals the future of modern aesthetics will be multimodal treatment plans and holistic, natural results
DGRO may stand out for investors looking for an ETF focused not only on the highest dividend yields, but on quality dividend payers likely to be stable.
NORTH CHICAGO, Ill. , March 9, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results 1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating...
1 Momentum Stock to Consider Right Now and 2 We Ignore
Three companies with a combination of excellent name recognition within their industries and strong free cash flow potential provide a stable investment option.
AbbVie (ABBV): Buy, Sell, or Hold Post Q4 Earnings?
Data shows a rise in specific treatment demand; a shift in patient consultation and the rising role of facial volume restoration
NORTH CHICAGO, Ill. , March 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate...
NORTH CHICAGO, Ill. , March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating...